• Publications
  • Influence
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available. Expand
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies.
It is suggested pemetrexed should not be recommended for the treatment of squamous cell carcinoma, but, because of efficacy and safety advantages, it may be preferable to other agents for treatment of patients with nonsquamous NSCLC. Expand
Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer.
The study was terminated after the interim analysis concluded that the study was highly unlikely to meet its primary end point, and no clinical benefit was observed from adding sorafenib to CP chemotherapy as first-line treatment for NSCLC. Expand
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.
This guideline update reflects changes in evidence since the previous guideline update and recommends all immune checkpoint therapy is recommended alone plus in the absence of contraindications. Expand
Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer.
Treatment with this dose and schedule of IP did not result in improved survival when compared with EP, and fewer patients receiving IP had grade 3/4 anemia, thrombocytopenia, neutropenIA, and febrile neutropania compared with patients receiving EP, but more had grade 2/4 diarrhea and vomiting. Expand